Acute Lymphocytic Leukemia Pipeline 2025

DelveInsight's "Acute Lymphocytic Leukemia Pipeline Insight 2025" report delivers extensive analysis on over 125 companies and more than 130 pipeline drugs in the Acute Lymphocytic Leukemia treatment arena. It includes thorough profiles of Acute Lymphocytic Leukemia pipeline drugs, encompassing clinical and nonclinical development stages. Additionally, it evaluates Acute Lymphocytic Leukemia pipeline therapeutics by product category, development phase, administration method, and molecular structure. It also points out discontinued pipeline products in this domain.

Explore our cutting-edge advancements in Acute Lymphocytic Leukemia studies. Get more details on our pioneering pipeline now! @ Acute Lymphocytic Leukemia Pipeline Outlook

Key Takeaways from the Acute Lymphocytic Leukemia Pipeline Report

• In August 2025, Pfizer disclosed a trial in Chinese patients with relapsed or refractory CD22-positive B-cell ALL. The goal is to verify the effectiveness, safety, and pharmacokinetics of inotuzumab ozogamicin in patients with relapsed or refractory B-cell ALL from mainland China.

• In August 2025, Juventas Cell Therapy Ltd. revealed a Phase II, single-arm, open-label, single-dose clinical trial, with the main aim to assess the effectiveness and safety of CNCT19 Cell Injection in treating CD19 positive Relapsed or Refractory acute lymphoblastic leukemia.

• In August 2025, Janssen Research & Development, LLC conducted a trial to establish the recommended Phase 2 dose(s) (RP2D[s]) of bleximenib in Phase 1 Part 1 (Dose Escalation) and to assess safety and tolerability at RP2D in Phase 1 Part 2 (Dose Expansion). The Phase 2 part aims to evaluate bleximenib's efficacy at the RP2D.

• In August 2025, Amgen organized a Phase I trial to evaluate the safety, effectiveness, and tolerability of subcutaneous (SC) blinatumomab for R/R B-ALL treatment, to determine the maximum tolerated dose (MTD), and recommended Phase 2 dose(s) (RP2D) of SC-administered blinatumomab.

• DelveInsight's Acute Lymphocytic Leukemia pipeline report illustrates a vibrant arena with over 125 active contributors developing more than 130 pipeline treatments for Acute Lymphocytic Leukemia care.

• The prominent Acute Lymphocytic Leukemia Companies include Orca Biosystems, Inc, Jazz Pharmaceuticals, Shenzhen TargetRx, Inc, Cellectis, ADC Therapeutics S.A., Kunming Hope of Health Hospital, Beam Therapeutics Inc., Shenzhen BinDeBio Ltd., Kite, A Gilead Company, Sumitomo Pharma America, Inc., In8bio Inc., Fate Therapeutics, Sichuan Baili Pharmaceutical Co., Ltd., Janssen Research & Development, LLC, Medolution Ltd., Kymera Therapeutics, Inc., Kite, A Gilead Company | Gilead Sciences, Newave Pharmaceutical Inc, Servier, Meryx, Inc., Armaceutica, Inc., Hangzhou Qihan Biotech Co., Ltd., Nanjing Bioheng Biotech, Sanofi, Syndax Pharmaceuticals, Vincerx Pharma, Inc., and others.

• Promising Acute Lymphocytic Leukemia Pipeline Therapies include Omitted Doxorubicin, Blinatumomab, Dexamethasone, Vincrisitne, Recombinant Asparaginase, Inotuzumab Ozogamicin, and others.

Stay updated on the latest innovations in Acute Lymphocytic Leukemia treatments. Access for updates and join the advancement in care @ Acute Lymphocytic Leukemia Clinical Trials Assessment

Acute Lymphocytic Leukemia Emerging Drugs Profile

• Orca-T: Orca Biosystems, Inc. Orca-T is an experimental high-precision cell therapy aimed at replacing a patient's cancerous blood and immune system with a healthy one while significantly reducing the risk of GvHD and other potentially fatal complications. In the Phase Ib/II study, compared to a concurrent, nonrandomized single-center comparator for allogeneic transplant patients, Orca-T showed initial evidence of substantially higher GvHD-free, relapse-free survival rates after 1 year, better relapse-free survival, and lower chronic GvHD rates. The drug is currently in Phase III development for ALL.

• TGRX-814: Shenzhen TargetRx, Inc. TGRX-814 is a highly selective inhibitor of BCL2 (over BCL-XL) for treating CLL with or without the del(17p)/TP53 mutation, NHL, SLL, DLBL, MM, etc. Notably, TGRX-814 has an excellent selectivity profile for BCL-XL. TGRX-814 is refined and optimized through classical bioisosterism and molecular simulation techniques. In-vitro and in-vivo tests indicate that TGRX-814 enhances oral metabolism, boosts in vivo exposure, and decreases compound clearance while preserving in vitro and in vivo activity. Furthermore, TGRX-814 achieved over 2-fold higher bioavailability than the marketed drug Venetoclax, leading to a notable efficacy boost. The drug is in Phase I/II development for ALL.

• UCART22: Cellectis UCART22 is one of Cellectis' wholly owned, allogeneic, off-the-shelf gene-edited T-cell product candidates for relapsed and refractory B-cell acute lymphoblastic leukemia (R/R B-ALL). Like CD19, CD22 is a cell surface antigen expressed from the pre-B-cell stage through mature B-cells. CD22 expression is found in more than 90% of B-ALL patients. It is currently in Phase I development. The drug is in Phase I trials for ALL.

The Acute Lymphocytic Leukemia Pipeline Report Provides Insights into

• The report furnishes comprehensive details on organizations advancing therapies for Acute Lymphocytic Leukemia, including the total treatments each company is developing.

• It examines various therapeutic candidates categorized into initial, intermediate, and advanced development stages for Acute Lymphocytic Leukemia management.

• Acute Lymphocytic Leukemia Companies are engaged in precision therapeutics with ongoing and paused (inactive or halted) initiatives.

• Acute Lymphocytic Leukemia Drugs in progress, sorted by development phase, delivery route, target receptor, standalone or combined therapy, unique action mechanisms, and molecular category.

• Comprehensive review of partnerships (corporate alliances and academic ties), licensing deals, and funding information to drive future growth in the Acute Lymphocytic Leukemia market.

Explore more on Acute Lymphocytic Leukemia drug prospects in our innovative research and development efforts @ Acute Lymphocytic Leukemia Unmet Needs

Acute Lymphocytic Leukemia Companies Orca Biosystems, Inc, Jazz Pharmaceuticals, Shenzhen TargetRx, Inc, Cellectis, ADC Therapeutics S.A., Kunming Hope of Health Hospital, Beam Therapeutics Inc., Shenzhen BinDeBio Ltd., Kite, A Gilead Company, Sumitomo Pharma America, Inc., In8bio Inc., Fate Therapeutics, Sichuan Baili Pharmaceutical Co., Ltd., Janssen Research & Development, LLC, Medolution Ltd., Kymera Therapeutics, Inc., Kite, A Gilead Company | Gilead Sciences, Newave Pharmaceutical Inc, Servier, Meryx, Inc., Armaceutica, Inc., Hangzhou Qihan Biotech Co., Ltd., Nanjing Bioheng Biotech, Sanofi, Syndax Pharmaceuticals, Vincerx Pharma, Inc., and others.

Acute Lymphocytic Leukemia (ALL) pipeline report assesses the therapeutic potential of pipeline drugs by Route of Administration. Products are grouped under different ROAs, including

• Oral

• Intravenous

• Subcutaneous

• Parenteral

• Topical

Acute Lymphocytic Leukemia Products have been categorized under various Molecule types such as

• Recombinant fusion proteins

• Small molecule

• Monoclonal antibody

• Peptide

• Polymer

• Gene therapy

Discover the newest developments in Acute Lymphocytic Leukemia Treatment by checking our site. Keep up with our progress in reshaping the future of disease @ Acute Lymphocytic Leukemia Market Drivers and Barriers, and Future Perspectives

Scope of the Acute Lymphocytic Leukemia Pipeline Report

• Coverage- Global

• Acute Lymphocytic Leukemia Companies- Orca Biosystems, Inc, Jazz Pharmaceuticals, Shenzhen TargetRx, Inc, Cellectis, ADC Therapeutics S.A., Kunming Hope of Health Hospital, Beam Therapeutics Inc., Shenzhen BinDeBio Ltd., Kite, A Gilead Company, Sumitomo Pharma America, Inc., In8bio Inc., Fate Therapeutics, Sichuan Baili Pharmaceutical Co., Ltd., Janssen Research & Development, LLC, Medolution Ltd., Kymera Therapeutics, Inc., Kite, A Gilead Company | Gilead Sciences, Newave Pharmaceutical Inc, Servier, Meryx, Inc., Armaceutica, Inc., Hangzhou Qihan Biotech Co., Ltd., Nanjing Bioheng Biotech, Sanofi, Syndax Pharmaceuticals, Vincerx Pharma, Inc., and others.

• Acute Lymphocytic Leukemia Pipeline Therapies- Omitted Doxorubicin, Blinatumomab, Dexamethasone, Vincrisitne, Recombinant Asparaginase, Inotuzumab Ozogamicin, and others.

• Acute Lymphocytic Leukemia Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination

• Acute Lymphocytic Leukemia Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III

For an extensive summary of our recent findings and upcoming strategies, review the complete Acute Lymphocytic Leukemia Pipeline details on our site @ Acute Lymphocytic Leukemia Emerging Drugs and Companies

Table of Content

1. Introduction

2. Executive Summary

3. Acute-Lymphocytic-Leukemia: Overview

4. Pipeline Therapeutics

5. Therapeutic Assessment

6. Acute-Lymphocytic-Leukemia- DelveInsight's Analytical Perspective

7. Late Stage Products (Phase III)

8. Orca-T: Orca Biosystems, Inc.

9. Drug profiles in the detailed report.....

10. Mid Stage Products (Phase II)

11. Product Name: Company Name

12. Drug profiles in the detailed report.....

13. Early Stage Products (Phase I/II)

14. TGRX-814: Shenzhen TargetRx, Inc.

15. Drug profiles in the detailed report.....

16. Preclinical and Discovery Stage Products

17. Drug Name: Company Name

18. Drug profiles in the detailed report.....

19. Inactive Products

20. Acute-Lymphocytic-Leukemia Key Companies

21. Acute-Lymphocytic-Leukemia Key Products

22. Acute-Lymphocytic-Leukemia- Unmet Needs

23. Acute-Lymphocytic-Leukemia- Market Drivers and Barriers

24. Acute-Lymphocytic-Leukemia- Future Perspectives and Conclusion

25. Acute-Lymphocytic-Leukemia Analyst Views

26. Acute-Lymphocytic-Leukemia Key Companies

27. Appendix

About Us

DelveInsight is a premier market research and consulting firm focused on healthcare, offering high-quality intelligence and analysis to guide strategic decisions. Our expert team, with profound knowledge of life sciences and healthcare, provides tailored research services and insights worldwide. Reach out for reliable, precise, and timely data to maintain a competitive edge.

Contact Us 

Kanishk

kkumar@delveinsight.com